Why the study?
Does aspirin 75-100 mg/day improve the benefit:risk ratio compared to other doses in acute coronary syndrome patients?
Does aspirin 75-100 mg/day improve the benefit:risk ratio compared to other doses in acute coronary syndrome patients?
Aspirin doses of 75-100 mg/day appear to offer the optimal benefit-to-risk ratio for secondary prevention in acute coronary syndrome patients.
No takes yet. Share an insight, caveat, or question.
Supports current ACS aspirin use without practice change; leaves open need for confirmatory RCTs.
DiNicolantonio et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: